Primary Sclerosing Cholangitis - Pipeline Review, H1 2017

Size: px
Start display at page:

Download "Primary Sclerosing Cholangitis - Pipeline Review, H1 2017"

Transcription

1 Primary Sclerosing Cholangitis - Pipeline Review, H1 2017

2 Primary Sclerosing Cholangitis - Pipeline Review, H BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0) or reportstore@bioportfolio.com 2

3 Primary Sclerosing Cholangitis - Pipeline Review, H Primary Sclerosing Cholangitis - Pipeline Review, H Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H1 2017, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape. Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 8, 2 and 5 respectively. Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal). 3

4 - The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industryspecific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Additional Details Publisher : Global Markets Direct Reference : GMDHC8963IDB Number of Pages : 85 Report Format : PDF Publisher Information : 4

5 5

6 Table Of Contents for Primary Sclerosing Cholangitis - Pipeline Review, H [Report Updated: ] Table of ContentsList of TablesList of FiguresIntroductionGlobal Markets Direct Report CoveragePrimary Sclerosing Cholangitis - OverviewPrimary Sclerosing Cholangitis - Therapeutics DevelopmentPipeline OverviewPipeline by CompaniesProducts under Development by CompaniesPrimary Sclerosing Cholangitis - Therapeutics AssessmentAssessment by TargetAssessment by Mechanism of ActionAssessment by Route of AdministrationAssessment by Molecule TypePrimary Sclerosing Cholangitis - Companies Involved in Therapeutics DevelopmentAllergan PlcBiotie Therapies CorpChemoCentryx IncDr. Falk Pharma GmbHGenextra SpaGilead Sciences InciCo Therapeutics Inc.Iltoo PharmaNGM Biopharmaceuticals IncSancilio & Company IncShire PlcTakeda Pharmaceutical Company LtdPrimary Sclerosing Cholangitis - Drug Profilesaldesleukin - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressberberine ursodeoxycholate - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressbertilimumab - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCCX Drug ProfileProduct DescriptionMechanism Of ActionR&D Progresscenicriviroc mesylate - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressGS Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressHTD Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressmaralixibat chloride - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressNGM Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressnorursodeoxycholic acid - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressobeticholic acid - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSC Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSC Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressStem Cell Therapy for Primary Sclerosing Cholangitis - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progresstimolumab - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressvedolizumab - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressPrimary Sclerosing Cholangitis - Dormant ProjectsPrimary Sclerosing Cholangitis - Discontinued ProductsPrimary Sclerosing Cholangitis - Product Development MilestonesFeatured News & Press ReleasesJan 05, 2017: Phenex Receives $100 Million Milestone Payment From GileadAug 26, 2016: Biotie: BTT1023 Receives Orphan Drug Designation in the United StatesJun 07, 2016: Immune Pharmaceuticals and Hadasit File a Joint Patent on the Oral Use of Anti-Eotaxin Monoclonal Antibodies, Including Bertilimumab, for the Treatment of GI and Liver DiseasesApr 16, 2016: Investigational treatment provides hope for some chronic liver disease sufferersjan 07, 2016: Tobira Therapeutics Announces Initiation of Program to Evaluate Cenicriviroc for the Treatment of Primary Sclerosing CholangitisNov 09, 2015: NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD's The Liver Meeting 2015Nov 03, 2015: Intercept Announces Data to be Presented at the 2015 AASLD Annual MeetingMar 31, 2015: Biotie announces start of patient enrolment into Phase 2a clinical study with BTT1023 in primary sclerosing cholangitisfeb 17, 2015: BTT1023 receives positive opinion for Orphan Drug Designation from COMPJul 24, 2014: Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant fundingnov 18, 2013: Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver DiseasesSep 26, 2013: Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver DiseasesAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer 6

7 How to Buy... Primary Sclerosing Cholangitis - Pipeline Review, H [Report Updated: ] Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0) We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $2000 Single User Price $4000 Site License Price $6000 Enterprise License Price Payment Options: (please tick one) Online Credit Card (we will you the invoice with a payment link) Direct Wire Transfer (we will you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0) We will be delighted to give you our personal attention. 7